Altimmune with ticker code (ALT) have now 7 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 30 and 12 with the average target price sitting at 23.14. With the stocks previous close at 12.67 this now indicates there is a potential upside of 82.6%. There is a 50 day moving average of 7.03 and the 200 moving average now moves to 8.4. The market capitalisation for the company is $548m. Find out more information at: https://altimmune.com
The potential market cap would be $1,000m based on the market concensus.
Altimmune, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune in September 2015. Altimmune was founded in 1997 is headquartered in Gaithersburg, Maryland.
